What is AOD-9604?
AOD-9604 is a modified fragment of growth hormone investigated for metabolic effects. Animal experiments and the later human obesity program tell different parts of its story.
Biological role or research focus
Growth-hormone fragment studied for obesity.
A fragment is not interchangeable with growth hormone. Research into fat metabolism does not establish effective weight loss.
Names you may encounter
AOD 9604 · AOD9604
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Modified growth-hormone fragment
- Main research area
- Fat metabolism research
- Evidence featured
- Animal / laboratory study
- Source check
- October 4, 2026
Quick answers
- Is AOD-9604 FDA approved?
- No. No FDA-approved drug contains AOD-9604. Source ↗
- Is AOD-9604 safe?
- AOD-9604 is an unapproved growth-hormone fragment. Oral trials exist, but FDA found too little safety data, noted serious events of unclear cause, and flagged risks for injected products. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is AOD-9604 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.3 Growth hormone fragments). Source ↗
- Has the FDA taken action over AOD-9604?
- Yes. Our records list 1 FDA action naming it, most recently on April 1, 2020: FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing AOD 9604 among bulk substances that are not eligible for 503A compounding exemptions. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Fat oxidation experiment (2001) | Animal / laboratory study | Obese and lean mice, plus cells expressing the human growth-hormone receptor. |
| AOD9604 with and without hyaluronic acid in knee OA (2015) | Animal study | 32 mature rabbits with collagenase-induced knee osteoarthritis. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal / laboratory study · 2001
Fat oxidation experiment
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
- Population / model
- Obese and lean mice, plus cells expressing the human growth-hormone receptor.
- Study design
- 14 days comparing AOD-9604, growth hormone, and saline; metabolic and receptor assays.
- Main finding
- AOD-9604 reduced weight gain and increased fat oxidation in obese mice. Unlike growth hormone, it did not activate the tested growth-hormone receptor or produce the same glucose effects.
- Limits & context
- These animal results generated a hypothesis. They do not establish effective human obesity treatment, nor validate a commercial injectable preparation.
Animal study · 2015
AOD9604 with and without hyaluronic acid in knee OA
Was cartilage damage affected in a chemically induced joint model?
- Population / model
- 32 mature rabbits with collagenase-induced knee osteoarthritis.
- Study design
- Four groups received joint injections of saline, hyaluronic acid, AOD9604, or their combination; morphology, histology, and lameness assessed.
- Main finding
- The active groups had better reported cartilage-damage scores than saline. The combination group had better scores than either single agent and a shorter lameness period.
- How to read it
- This is a distinct preclinical joint-research question. It does not overturn the limitations of the human weight-loss program.
- Limits & context
- Chemically induced rabbit OA and local joint exposure do not establish human cartilage regeneration, clinical arthritis benefit, or effective obesity treatment.
Source: Kwon and Park · Annals of Clinical & Laboratory Science · 2015 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming AOD-9604 as an intervention was found on ClinicalTrials.gov when we last checked (November 14, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗Risks & interactions
AOD-9604 is an unapproved growth-hormone fragment. Oral trials exist, but FDA found too little safety data, noted serious events of unclear cause, and flagged risks for injected products.
Human experience comes mainly from oral obesity trials summarized by the developer; FDA could not identify or rule out a safety signal. FDA found no human data for injected or skin-applied forms and no human pharmacokinetic studies.
Unassessed: little human safety data
Take extra care with: Cancer, now or in the past
Warning signs in animal or lab studies: Liver problems
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Serious adverse events in oral studies included diarrhea, chest tightness and cancers; FDA could not tell whether AOD-9604 caused them
- Severe chest tightness and euphoria reported as possibly related in intravenous studies (FDA review)
- FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
Harms seen in animal or lab studies
- Bone-turnover marker (osteocalcin) changes in a long-term rat study (FDA review)
- Minimal to slight liver-cell vacuolation in a long-term monkey study, a possible sign of liver injury (FDA review)
- Equivocal results in mutation and chromosome-damage tests (FDA review)
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA briefing document: AOD-9604 (Pharmacy Compounding Advisory Committee, 2024) ↗ · FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · AOD-9604 fat-oxidation study in obese mice (2001) ↗
Safety evidence & remaining uncertainty
The FDA assessment highlights uncertain safety and product-characterization issues. Oral trial experience cannot establish the safety of an injected preparation; a route change can alter exposure and risk.
Source: FDA briefing: AOD-9604 and obesity ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "AOD-9604". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.3 Growth hormone fragments
Named explicitly ("AOD-9604"). source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing AOD 9604 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
The FDA’s 2024 assessment describes an unsuccessful obesity-development program. In the OPTIONS study, 536 people enrolled and 502 were randomized; oral AOD-9604 did not significantly outperform placebo at the primary weight-loss endpoint. This is a regulatory account of an unpublished study, not a peer-reviewed trial article.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
Early experiments examined fat oxidation and fat breakdown. AOD-9604 did not activate the tested growth-hormone receptor in the way intact growth hormone did, so it should not be treated as a smaller interchangeable version of that hormone.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- A fragment is not interchangeable with growth hormone. Research into fat metabolism does not establish effective weight loss.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Why do mouse results and human results differ?
Species, metabolism, exposure, and study endpoints differ. Reduced weight gain in a short mouse experiment does not predict meaningful weight loss in a human trial.
Does “growth-hormone fragment” imply the same effects as growth hormone?
No. The cited receptor experiments found different behavior. Neither the name nor the fragment relationship establishes equivalent benefits.
What does the AOD9604 with and without hyaluronic acid in knee OA study show, and what does it not?
This is a distinct preclinical joint-research question. It does not overturn the limitations of the human weight-loss program. Chemically induced rabbit OA and local joint exposure do not establish human cartilage regeneration, clinical arthritis benefit, or effective obesity treatment.
Source: Kwon and Park · Annals of Clinical & Laboratory Science · 2015 ↗
References & editorial record
- FDA · Compounding safety concerns ↗
- FDA briefing: AOD-9604 and obesity ↗
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. ↗
- Kwon and Park · Annals of Clinical & Laboratory Science · 2015 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
